Link: https://youtu.be/edbIJ7PpVlc

Duration: 125 min

Transcript: Download plain text

Short Summary

This is an interview with Harvard longevity researcher David Sinclair covering his lab's epigenetic reprogramming work (including ER-100/OSK gene therapy and an oral rejuvenation cocktail) and AI-accelerated aging discovery. Sinclair shares his personal routines on fasting, protein cycling, exercise, sleep, and supplements, while discussing controversial topics like Brian Johnson's self-experimentation, GLP-1 drugs as potential longevity medications, and his $8/month Lifespan.com project. He also outlines his "information theory of aging," argues the first person to live to 150 may already be alive, and emphasizes social relationships, stress management, and evidence-based lifestyle fundamentals.

Key Quotes

1. "I prefer to think of aging as a disease because otherwise we're not really treating it." (00:09:09)
2. "probably the first person to live to 150 is already alive." (00:14:49)
3. "I'm not doing this to be a scientist. I'm doing this because I'm on a mission and my life is irrelevant. Um I would literally die to achieve this mission." (00:18:57)
4. "We just did something in a few months that would have taken us 160 years." (01:47:19)
5. "It's as close to a longevity drug as we probably have right now given what we're seeing." (01:40:14)

Detailed Summary

Episode Summary: David Sinclair on Longevity, Epigenetic Reprogramming, and AI-Accelerated Aging Research

1. David Sinclair and the Scope of the Interview

David Sinclair is a Harvard Medical School aging researcher whose lab employs as many as 40 people. The interview covers cellular reprogramming, fasting, nutrition, exercise, sleep, supplements, cardiovascular monitoring, biohacking, GLP-1 drugs, AI-assisted discovery, and the social determinants of healthy aging.

• Sinclair is the author of Lifespan, released around 2019, and co-founder of Metro Biotech.
• He describes aging as a disease that medicine should treat rather than an inevitable biological condition.
• The host recalls recording his first American podcast episode in Sinclair’s Harvard office in 2019 using two iPhones and one USB microphone; the host says he was 12 years old at the time.
• Sinclair traces part of his mission to a promise he made to his grandmother at age four after she had lived through World War II in Europe.
• He organizes longevity interventions into three broad categories: lifestyle, drugs, and supplements.
• Sinclair says his COVID-era divorce accelerated his own aging and uses the experience as a personal example of the effect of major stress.

2. The Information Theory of Aging and Partial Cellular Reprogramming

Sinclair’s central theory treats aging primarily as an erosion of epigenetic information rather than simply accumulated DNA damage. He compares DNA to music, the epigenome to the device reading it, and aging to damage to that device or its software.

• His lab’s work appeared on the cover of Nature in 2020 with what Sinclair describes as the first safe reversal of aging in an animal: a mouse whose blindness was cured.
• Sinclair says the result was later reproduced in other animals, including monkeys, and in additional tissues.
• A 2023 mouse study found that disrupting the normal bundling and looping of DNA caused cells to lose their identity and function and accelerated aging; Sinclair says that project took 13 years to develop.
• The treatment is called ER-100, or “epigenetic reversal 100,” and is described as a gene-therapy approach using a virus-like particle.
• ER-100 delivers OSK, a subset of the four Yamanaka reprogramming factors. OSK is normally active early in life and is associated with the embryonic program that resets cellular age after fertilization.
• Sinclair says the important breakthrough was omitting the M gene, or c-MYC, from the four-factor system. The result was approximately 75% age reversal without fully converting mature cells into stem cells.
• Complete reprogramming can cause cancer or embryonic death within days, which is why Sinclair’s lab pursued partial reprogramming.
• The eye was chosen as an early target partly because it is enclosed and limits the treatment’s spread. Sinclair credits his student Wang with advocating for the eye over easier targets such as the liver.
• The partial-reprogramming project ran from approximately 2014 to 2017, and Sinclair says Wang nearly quit when experiments either failed or caused cancer.
• Sinclair says the work has moved into human clinical use for vision loss and has also shown effectiveness in animal models involving glaucoma, macular degeneration, nerve damage, and laser-induced eye injury.

3. Oral Reprogramming and Predictions About Human Lifespan

Sinclair describes an oral rejuvenation treatment as a possible alternative to gene therapy. He says the lab has spent five years developing the approach, which has produced rejuvenation effects in old mice.

• The oral treatment is described as a pill or cocktail that improved memory and skin quality in old mice.
• The mice received the treatment orally three days per week for one month.
• Sinclair says the mechanism involves TET enzymes, which remove chemical marks from DNA. When TET enzymes are inhibited or removed, the cells do not become younger through the treatment.
• Sinclair predicts that the first person to live to 150 years is already alive and expects a child born today to reach the 22nd century.
• He says colleagues advised him against publicly citing age 150 because of credibility concerns, although he says they agree with the prediction privately.
• He refers to longevity escape velocity, the idea that each day lived could create more additional days through future medical progress.
• Sinclair also says his lab is approximately eight years ahead of what it has publicly published.

4. Fasting, Hunger, and Metabolic Switching

Sinclair generally eats one meal per day, or two when socializing, and regards three meals plus snacks as a pattern promoted through marketing. He treats fasting as a way to alternate between periods of abundance and biological adversity.

• He reports fasting for as long as two weeks using zero-calorie drinks, tea, occasional celery, vitamins, and other supplements.
• After roughly three days without food, Sinclair says he feels mentally clear, energized, and unusually well. He links that state to chaperone-mediated autophagy, a process that clears misfolded and modified proteins.
• During the first 24 hours without food, the discussion describes the body using blood sugar and liver glycogen before the liver regulates glucose through ketones.
• Sinclair proposes that fasting increases bile output and that microbiome activity can convert cholic acid into molecules that enter the bloodstream and influence epigenetic regulation.
• A Nature paper is cited as finding that fasting increased the microbiome’s production of bile-derived molecules and short-chain fatty acids.
• Sinclair frames health as cycling between “abundance” and “adversity,” arguing that remaining constantly in either state may accelerate aging.
• He monitors longer fasts with a continuous glucose monitor, smart rings, blood tests, and a Wings smart scale that he has held since 2013.
• He takes a daily nutrient pack containing substances such as vitamins B and C, along with medicines, to address deficiencies during prolonged fasting.
• Prolonged fasting can cause muscle loss, so Sinclair says he increases his workouts and uses the scale to check that lean mass is not declining.
• He cautions against extended fasting for very lean people with little body fat and for older adults, because the risk of muscle loss is greater.
• For beginners, he recommends skipping one meal and replacing it with water, black tea, coffee, or low-calorie drinks while tolerating the initial hunger.
• He says he delayed eating until late lunch for about 30 years and that morning or late-night food felt “weird” after roughly two weeks of adjustment.
• During discussion of long fasts, he describes bowel changes as largely gas, jokingly calling them “phantom poo,” and proposes that slower gut motility or microbiome changes could have wider effects.

5. Calorie Restriction, Protein Cycling, and Time-Restricted Feeding

Sinclair distinguishes the evidence for fasting and calorie restriction in animals from the much weaker evidence in humans. He argues that timing, protein quality, and periods without abundant food may matter as much as the total number of calories.

• Sinclair says there is no prospective, placebo-controlled human study showing that calorie restriction extends lifespan.
• He acknowledges shorter studies lasting a couple of years, biomarker improvements, animal research, and anecdotal or historical evidence, while describing properly nourished calorie restriction in animals as beneficial for health and longevity.
• He criticizes the original two-decade macaque calorie-restriction study for comparing a healthy diet with what he characterizes as a junk-food diet rather than equivalent diets.
• Sinclair says later macaque findings were mixed and depended on factors such as veterinary care and the animals’ environment.
• He cites Rosalyn Anderson, whom he trained about 20 years earlier, as leading the University of Wisconsin monkey study that found longer life, less cancer, and lower disease burden among calorie-restricted monkeys.
• He says two laboratories that initially disagreed eventually concluded that calorie restriction extended lifespan in the monkeys.
• Tea and coffee polyphenols are described as activating protective enzymes, while hunger, exercise, and compounds from stressed plants are presented as signals that shift the body from growth and reproduction toward maintenance.
• An NIH mouse study led by Rafa de Cabo reportedly found substantially longer life when similar calories were consumed within a restricted time window rather than continuously, regardless of whether the diet was dominated by protein, carbohydrates, or fat.
• Sinclair contrasts protein-maxing bodybuilding diets with longevity science. Valine, isoleucine, and leucine are highlighted as branched-chain amino acids more abundant in animal protein, with high BCAA intake shortening lifespan in animals.
• He says protein restriction has improved metabolic markers in short-term human studies.
• His practical approach is to pulse protein and calories: use meat when building muscle, favor plant protein, and create periods without meat or large meals so mTOR is not constantly active.
• He says he does not attempt to eliminate protein entirely.

6. Exercise, Sleep, and Stress Management

Sinclair recommends a mixed exercise program rather than a single discipline. His preferred combination includes resistance training, balance work, aerobic conditioning, and activities that raise heart rate and breathing.

• He recommends combining weightlifting, balance work, and aerobic or VO2-max training.
• He suggests becoming breathless at least three times per week for 10 minutes and says 10 minutes of sufficiently vigorous sex can count toward the routine.
• If high-intensity exercise is not possible, he recommends low-and-slow “zone two” activity such as walking or using a standing desk.
• Sinclair says he rarely sits during the day and describes VO2 max as correlated with very long life.
• Sleep needs vary by person, with some people requiring seven hours and others eight.
• Sinclair reports functioning on five hours of sleep, with HRV in the 80s to 90s and sleep efficiency in the 90s to nearly 100%.
• He attributes his deep sleep partly to avoiding late caffeine, breathing practices, meditation, and a glycine supplement made by his partner, Serena.
• He says he has accumulated approximately 1,500 to 2,000 nights of Whoop sleep data.
• The episode’s key wearable takeaway is that “you’re sleeping less than you think you are.” Late caffeine, alcohol, hot rooms, and too many blankets are identified as major disruptors.
• For stress, Sinclair uses a mental image of an orchard on Cape Cod as a “happy place.”
• He says it took him 50 years to learn not to ruminate over worries.

7. Resveratrol, NMN, and Sinclair’s Core Supplement and Drug Stack

At age 57, Sinclair says his daily regimen has remained essentially unchanged since Lifespan and is documented around page 304 of the book. His stack includes resveratrol, NMN, aspirin, alpha-lipoic acid, and prescription cardiovascular drugs.

• He takes about one teaspoon, or roughly one gram, of resveratrol most mornings for approximately 20 years, usually with olive oil or Greek or vegan yogurt.
• Sinclair’s lab showed in 2003 that resveratrol directly activates sirtuin 1, or SIRT1, an enzyme that removes chemical modifications and stabilizes the epigenome.
• After a 2010 Pfizer paper characterized the activation as an artifact, Sinclair says his lab spent three years establishing the atomic mechanism.
• He cites a 2013 paper and a mouse with a blocking SIRT1 mutation as evidence that resveratrol loses its health and lifespan effects without functional SIRT1.
• He describes resveratrol as a molecule from stressed plants that activates or “resets” SIRT1.
• Sinclair characterizes disputes over resveratrol and NAD precursors as “typhoons in a teacup,” saying sirtuin activators are not controversial within his scientific circles.
• He explains that SIRT1 uses NAD as a cofactor to remove chemical marks from the epigenome, and that higher NAD levels accelerate that process.
• Sinclair cites a mouse paper he describes as resubmitted that found NMN benefits in old mice and extended lifespan, especially in females.
• He also cites studies involving obese, pre-diabetic, and highly fit people in which NMN improved lipids, cholesterol, blood pressure, and body weight.
• Sinclair disputes the claim that white-blood-cell NAD levels decline with age and says lower muscle NAD levels are associated with lower metabolic activity or metabolic syndrome.
• Sinclair co-founded Metro Biotech, which began NMN clinical trials. Although he objected, the company’s legal team told the FDA that NMN could not be sold during the trials.
• He says the FDA initially accepted that position but did not enforce it; a court case later reversed the position and NMN sales were allowed.
• Sinclair takes an 81-milligram baby aspirin daily and says the dose matches an earlier clinical trial rather than being uniquely superior to 100 milligrams.
• He contrasts his choice with the American Medical Association’s conclusion that baby aspirin is not justified for the general population because bleeding risk can outweigh reduced cardiovascular events; he says he takes it because he has high lipoprotein(a).
• He has taken alpha-lipoic acid for more than a decade, citing his PhD work on it, and also takes a statin.
• Sinclair says he is considering a PCSK9 inhibitor, which he describes as more effective but costly for his family.

8. Cardiovascular Testing and Pharmaceutical Strategies

Sinclair’s personal cardiovascular history led him to reconsider a low-carbohydrate diet and adopt more aggressive monitoring. His current approach combines dietary change, cholesterol-lowering medication, imaging, and a less-established supplement.

• Sinclair says his cholesterol rose into the 400s while following a low-starch, low-carbohydrate diet before he brought it back down.
• After a non-invasive Cleerly scan showed mild plaque progression, he adopted a Mediterranean, low-fat, low-protein diet.
• He identifies driving LDL very low with Repatha or using a PCSK9 inhibitor as potential plaque-reversal strategies and says he has a prescription for a recently available oral PCSK9 inhibitor.
• He cites a study of about 1,000 people in China suggesting that nattokinase may remove plaque, while acknowledging that the evidence is imperfect.
• Sinclair takes approximately 10,000 units of encapsulated nattokinase each morning.
• He plans annual cardiovascular monitoring with carotid ultrasound and intima-media thickness measurements.
• Nattokinase is described as an enzyme from Japanese natto produced with bacteria such as Bacillus subtilis.
• The host says Repatha, administered every two weeks, sharply lowered his Apo B but that he stopped because he suspected brain fog.
• The host also takes Telmisartan, reports polymorphisms associated with cholesterol and blood-pressure elevation, and notes that combining a statin with ezetimibe can be effective at lowering cholesterol.
• Sinclair takes low-dose daily Cialis, or tadalafil, for general blood-flow benefits.
• He explains that Cialis began as an angina drug and that its erectile effect emerged as a side effect observed during trials.
• He cites his group’s 2012 finding that low blood flow can accelerate aging and can be improved through NMN and SIRT1.

9. The Evolution of Biohacking, Sauna, and Cold Exposure

The discussion presents biohacking as moving from an earlier culture of aggressive self-experimentation toward a more evidence-based and consumer-scrutinized field. Sinclair considers heat exposure substantially better studied than cold exposure.

• Between roughly 2017 and 2019, biohacking was dominated by self-experimentation associated with figures such as Ben Greenfield and Timothe Arena’s Biohackers Handbook.
• Sinclair says the field has since become more evidence-based and more willing to distinguish established data from anecdote.
• The COVID pandemic shifted longevity from a fringe activity into the mainstream by confronting people with mortality.
• He says physicians now have to learn about longevity because patients, amplified by AI, often know more than their doctors.
• When Sinclair and the host first met in 2019, there was little sauna evidence and essentially no cold-plunge evidence beyond a mouse study.
• Finnish-style sauna studies involving Nordic men reportedly show that regular use a few times per week is associated with substantially lower heart-disease rates.
• Sinclair rates the evidence for heat exposure as roughly 10–20 times stronger than the evidence for cold exposure, although he still enjoys cold plunges for subjective reasons.
• Brown fat in adults was only discovered approximately 30 years ago through PET scanning, often in depots on the back.
• Brown fat is described as highly metabolically active and packed with mitochondria.
• Converting white fat into brown or beige fat becomes harder with age, so Sinclair recommends starting cold exposure early.
• He describes sleeping cooler, including through products such as Eight Sleep beds, as a speculative way to encourage brown-fat accumulation.
• Scientific pushback has emerged against Wim Hof’s claims, with Sinclair suggesting that the effects may not be as large as they are marketed.

10. Epigenetic Clocks and Brian Johnson

Steve Horvath is credited with discovering the epigenetic clock, which measures chemical changes on DNA that change with time. Sinclair uses Brian Johnson’s N-of-1 results to illustrate both the promise and the limitations of consumer longevity data.

• Sinclair compares the chemical changes tracked by the epigenetic clock to scratches on a CD.
• His DunedinPACE score measures the rate of epigenome change through DNA methylation; a score of 1.0 represents one year of biological change per calendar year, and the measure does not account for telomeres.
• Brian Johnson publicly reported a DunedinPACE score of approximately 0.4, which Sinclair describes as one of the lowest paces of aging he has seen.
• Sinclair says the score could add decades of life if maintained, while Johnson’s approach remains N-of-1 self-experimentation rather than a clinical trial.
• Johnson reportedly acknowledges that distinction himself.
• Sinclair pushes back against colleagues who call Johnson “the worst thing” for the field, arguing that scientists had a marketing problem and that Johnson helped popularize the word “longevity,” which was rarely used before 2020.

11. GLP-1 Drugs as Potential Longevity Medications

Sinclair describes GLP-1 drugs as the closest current category to a longevity drug, particularly because of their effects on obesity and their possible effects in other organs. He is enthusiastic about their benefits but does not describe them as risk-free.

• Sinclair calls GLP-1s “as close to a longevity drug as we probably have right now,” especially for people with obesity.
• He cites emerging off-target benefits for brain health and immune function in addition to weight loss.
• One study is said to suggest that dementia protection from GLP-1 drugs is not attributable solely to weight loss.
• Risks include small but real rates of kidney issues and blindness; Sinclair explicitly says the drugs are “not perfectly safe.”
• He personally tried small GLP-1 doses, lost hunger, and lost weight easily, but did not remain on the drug long enough to assess longer-term effects.
• Novo Nordisk and Eli Lilly now describe themselves as longevity companies.
• The discussion cites approximately 1 billion people globally with obesity compared with approximately 500 million people who are starving.
• It also states that about 40% of U.S. adults have obesity.
• U.S. usage estimates cited in the discussion include approximately 11%, or 29 million people, who have used a GLP-1; another estimate puts ever-use at about 15%.
• The material says approximately two-thirds of users are currently taking a GLP-1, while 9% are aware of the drugs and 20% of households are affected.
• A cited estimate says approximately 45% of Americans are willing to try a GLP-1, with the figure attributed in the discussion to Johan Hari’s book.
• The discussion also mentions Andrew Huberman’s prediction that retatrutide could become a trillion-dollar drug.

12. AI-Accelerated Aging Research

Sinclair describes AI as dramatically compressing the time required to identify aging-related patterns and candidate compounds. The lab’s work combines biological data, protein modeling, chemical screening, and image analysis.

• Sinclair says the lab completed in a few months work that would previously have taken 160 years.
• A 19-year-old student who had been in the lab for only three weeks identified a data signature that experts had missed for 10 years.
• The student’s discovery is described as a possible “backup copy” to cellular software under the information theory of aging, tentatively called “reverse tail.”
• Demis Hassabis’s protein-folding breakthrough enabled three-dimensional modeling of more than 15,000 amino-acid structures.
• In silico chemical-docking capacity grew from billions to trillions of chemicals per year, compared with the millions traditional pharmaceutical screening could test on 96- or 384-well plates.
• The lab identified approximately 200 AI-suggested compounds that may reverse aging, ordered them online, and began testing them on human cells.
• The lab built an AI system that examines stained cells and determines whether 90-year-old skin cells are reverting toward a 20-year-old state.
• Within approximately two months, Sinclair expects the lab to consolidate a current three-ingredient mouse-aging cocktail into a single molecule deliverable as a supplement, drug, patch, or cream.

13. Social Relationships, Stress, and Emotional Aging

The interview places major life stress and social connection alongside diet, exercise, and sleep as factors that influence how people age. Sinclair argues that relationships can affect biological aging through both behavior and stress hormones.

• Harvard researcher Robert Waldinger found that mental attitude and social life are as important as blood pressure and cholesterol for healthy aging.
• A reliable partner was identified in that research as the strongest positive social factor.
• Major life stressors, including moving, breakups, family deaths, and illness, are described as age accelerators acting through cortisol.
• Exercise, diet, sleep, social life, and relaxation are presented as factors that can slow aging.
• Sinclair attributes years lost from his own biological age to the acute stress of his COVID-era divorce.
• His 87-year-old father is described as socially active and living better than he did in his 40s.
• Sinclair advises choosing a marriage partner for loyalty and honesty because people change over the course of decades.

14. Foundational Habits and Targeted Health Tools

Sinclair’s practical philosophy begins with established fundamentals before moving to more specialized tools. He says health optimization can help people, but excessive attention to imperfect data can become a source of stress.

• His basic recommendations are to avoid overeating, stay relatively lean, avoid excessive alcohol, do not smoke, exercise, and maintain body mass.
• He identifies a BMI of 22–24 as his preferred range.
• Sinclair shifted from a meat-centric diet to a more plant-focused diet in his 50s and reports major biomarker improvements afterward.
• He favors creatine and describes it as worth taking.
• He views stem cells as interesting and potentially helpful for joint repair, but not as a long-term solution.
• He considers CPAP important for people whose sleep is interrupted by nighttime oxygen deprivation. Other options he mentions include weight loss, reducing alcohol, using thinner pillows, and sleeping on the stomach.
• Sinclair is in favor of hyperbaric oxygen therapy and cites good evidence for brain and blood-flow benefits; he also reports personal improvements in wound healing.
• He recommends avoiding bright light at night and obtaining violet or blue light in the morning. He cites Japan-based mouse data in which violet-light-deprived mice developed shortsightedness.
• Sinclair wears a continuous glucose monitor regularly and says grapes and white rice produce particularly large glucose spikes for him.
• Giving a glucose monitor to his then-17-year-old son changed the son’s eating habits.
• He rejects grounding as not scientifically based, while still valuing nature exposure through seeing, touching, smelling, and listening to the natural environment.
• Sinclair prefers natural approaches to testosterone first, acknowledges that older people can benefit from therapy, and says there is no evidence that testosterone extends lifespan.
• He describes overdosing on vitamins, especially B vitamins, as one of the biggest wastes of money in longevity. Large continuous doses of vitamin C can become pro-oxidative, according to the discussion.
• The host reports having four polymorphisms associated with difficulty processing B vitamins and an MCV of approximately 101.
• The host says an intramuscular 500-microgram dose of methylated B12 caused B12-induced confusion or a “slippery” brain during a period that included Joe Rogan on Thursday and Naval Ravikant on Saturday.

15. Testing, Supplement Purity, and Function Health

The discussion emphasizes that a supplement’s biological plausibility is not enough; product identity, dose, and contamination also matter. Sinclair and the host also compare broad laboratory testing with the smaller number of tests in a typical physical.

• Omega-3 is described as having anti-inflammatory effects, although its value for preventing heart disease remains controversial.
• Both Sinclair and the host use Nordic Naturals 2X, which Sinclair says is distilled to reduce heavy metals such as cadmium and lead.
• Andrea Meyer’s Singapore study reportedly found that many commercial NMN supplements contained no NMN or only low amounts.
• Sinclair says his lab found endotoxin contamination in NMN bulk material and supplements severe enough to invalidate mouse-lifespan experiments.
• For supplement selection, he recommends companies that publish analytical specifications, hold GMP certification, and use USP labels.
• When purity data are unavailable, he advises consumers to ask companies directly for the relevant information.
• The host’s sponsored segment describes Function Health as offering more than 160 laboratory tests, compared with approximately 20 markers in a typical annual physical.
• The tests are described as covering hormones, heart and kidney health, and signals associated with more than 50 cancers.
• Testing twice per year is listed at $365, reduced to $340 with a $25 episode discount, with results shown in a dashboard.

16. Lifespan.com, Healthcare, and the Closing Outlook

Sinclair presents Lifespan.com as a community-based way to make current longevity research accessible outside traditional healthcare systems. The closing discussion contrasts the field’s early biohacking hype with its newer emphasis on evidence, data, and consumer scrutiny.

• Lifespan.com launched at a membership price of $8 per month.
• Membership includes a research-focused magazine published monthly at approximately 100 pages per issue.
• The magazine is written by active researchers and covers topics such as Steve Horvath’s epigenetic clock and the 2020 Nature paper proposing aging as loss of information rather than accumulated damage.
• Sinclair describes the project as a community-based alternative to government and HMO healthcare models, with the goal of making current research directly accessible to the public.
• He contrasts U.S. healthcare spending of close to 20% of GDP with poor comparative outcomes.
• He contrasts the hype and selling associated with biohacking in 2017–2019 with a later focus on evidence, data, and consumer scrutiny.
• His final advice is to treat health optimization as a fun hobby rather than an all-consuming obligation, because obsessing over imperfect sleep or other health data can itself become a stressor.